Real-World Effectiveness of Dupilumab in Adult and Adolescent Patients with Atopic Dermatitis: 2-Year Interim Data from the PROSE Registry

ConclusionsIn the real-world PROSE registry, patients with moderate-to-severe AD experienced sustained improvement in disease control, symptoms, and quality of life up to 2  years after initiating dupilumab treatment. Safety data were consistent with the known safety profile of dupilumab.Trial RegistrationClinicalTrials.gov identifier: NCT 03428646.Video abstract (MP4 20,717  kb)
Source: Dermatology and Therapy - Category: Dermatology Source Type: research